Targeting CLPB conquers venetoclax resistance regulated by p53 loss and renders acute myeloid leukemia (AML) cells sensitive to the co-treatment with Venetoclax and Azacitidine through the induction of pro-apoptotic proteins (80). Here, CLPB is linked to acute myeloid leukemia.